drugset

drugset / Trial / NCT06910384

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

NCT06910384 ↗

Phase 2 Terminated 1 enrolled New England Cell Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.

Timeline

Start: 2025-08-12
Primary completion: 2025-12-16
Completion: 2025-12-16

Outcome

Outcome not reported

Stopped: “organizational restructure”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	STR04	Cell therapy	—	Intravenous

Indications